Seeing Is Believing

Currently out of the existing stock ratings of Brian Abrahams, 324 are a HOLD (40.35%), 474 are a BUY (59.03%), 5 are a SELL (0.62%).
Analyst Brian Abrahams, currently employed at RBC, carries an average stock price target met ratio of 46.26% that have a potential upside of 31.84% achieved within 211 days.
Brian Abrahams’s has documented 1,551 price targets and ratings displayed on 49 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 08-Dec-2025.
Analyst best performing recommendations are on MLTX (MOONLAKE IMMUNOTHERAPEUTICS).
The best stock recommendation documented was for MLTX (MOONLAKE IMMUNOTHERAPEUTICS) at 9/29/2025. The price target of $10 was fulfilled within 11 days with a profit of $3.75 (60%) receiving and performance score of 54.55.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 13-Jul-2021
$14
$10.25 (273.33%)
$11
2 months 23 days ago
(22-Oct-2025)
0/5 (0%)
$8.36 (148.23%)
Buy
Since 18-Oct-2021
$15
$11.25 (300.00%)
$10
5 months 15 days ago
(30-Jul-2025)
0/5 (0%)
$11.53 (332.28%)
Buy
Since 13-Jul-2021
1 years 6 months 24 days ago
(21-Jun-2024)
0/1 (0%)
$26.23 (139.74%)
Buy
Since 13-Jul-2021
$9
$5.25 (140.00%)
2 years 8 months 2 days ago
(12-May-2023)
0/3 (0%)
$7.1 (373.68%)
Buy
2 years 9 months 17 days ago
(27-Mar-2023)
0/1 (0%)
$17.08 (114.48%)
Which stock is Brian Abrahams is most bullish on?
Which stock is Brian Abrahams is most reserved on?
What Year was the first public recommendation made by Brian Abrahams?